Lesson plan

Endocyte

Endocyte is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). , the company had 93 employees. The original president and CEO, Ron Ellis , was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by Novartis. Endocyte is advancing the first technology platform for the creation of small molecule drug conjugates (a.k.a. SMDCs), which consist of a small molecule linked to a potent drug, and is developing a pipeline of SMDCs together with non-invasive companion imaging agents for cancer, inflammatory diseases and kidney disease (autosomal-dominant polycystic kidney disease/ADPKDor PKD). Endocyte’s lead drug candidate is vintafolide, an investigational targeted cancer therapeutic in late-stage development. In 2012 marketing rights were acquired by Merck for $120 million in an upfront payment and up to $880 million in milestone payments. Vintafolide is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is expressed on many cancers, such as ovarian cancer, and a potent chemotherapy drug, a derivative of vinblastine. Endocyte retained rights to the development and commercialization of etarfolatide.…

Back to article

Article summary

Endocyte is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). , the company had 93 employees. The original president and CEO, Ron Ellis , was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by Novartis. Endocyte is advancing the first technology platform for the creation of small molecule drug conjugates (a.k.a. SMDCs), which consist of a small molecule linked to a potent drug, and is developing a pipeline of SMDCs together with non-invasive companion imaging agents for cancer, inflammatory diseases and kidney disease (autosomal-dominant polycystic kidney disease/ADPKDor PKD). Endocyte’s lead drug candidate is vintafolide, an investigational targeted cancer therapeutic in late-stage development. In 2012 marketing rights were acquired by Merck for $120 million in an upfront payment and up to $880 million in milestone payments. Vintafolide is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is expressed on many cancers, such as ovarian cancer, and a potent chemotherapy drug, a derivative of vinblastine. Endocyte retained rights to the development and commercialization of etarfolatide.…

Key claims

  1. date of establishment: 1996 — source: Wikipedia · confidence 0.95
  2. employees: 93 employees — source: Wikipedia · confidence 0.95

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. The record states that the date of establishment is "1996". What evidence would count against this claim?
  3. The record states that the employees is "93 employees". What evidence would count against this claim?
  4. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  5. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

  1. Wikipedia https://en.wikipedia.org/w/index.php?oldid=1359503296

Key claims and bibliography are generated from the same tracked claims and sources as the article page.